Capricorn Venture Partners announced today that its Capricorn Health-tech Fund raised €42 million in a first closing which took place on December 22, 2010.
Late 2009 Capricorn Venture Partners launched the Capricorn Health-tech Fund (CHF) focusing on early to mid stage human health-technology companies in Europe. Capricorn Venture Partners defines health-technology as any technology based product used for the prevention, the diagnosis or the treatment of diseases and medical indications in humans. This includes the following subsectors: biopharmaceutical and pharmaceutical drugs, vaccines, medical devices, medical imaging, diagnostics, (research) equipment, nutraceuticals and functional foods.
In addition to a number of private investors and two universities the investors in this first close include Dexia Insurance Belgium, FPIM (Federale Participatie- en Investeringsmaatschappij), PMV (ParticipatieMaatschappij Vlaanderen), SRIW (Société Régionale d'Investissement de Wallonie) and Quest for Growth.
More information: www.capricorn.be/en/news
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
